Verteporfin

Generic Name: Verteporfin

Brand Names: Visudyne

Drug Type: Small Molecule

Chemical Formula: C_₄₁H_₄₂N_₄O_₈

CAS Number: 129497-78-5

Unique Ingredient Identifier: WU713D62N9

Background: Verteporfin, marketed as Visudyne, is a benzoporphyrin derivative. It is used as a photosensitizer in photodynamic therapy to eliminate abnormal blood vessels in wet form macular degeneration. Verteporfin accumulates in these abnormal blood vessels and, when stimulated by nonthermal red light with a wavelength of 693 nm in the presence of oxygen, produces highly reactive short-lived singlet oxygen and other reactive oxygen radicals, resulting in local damage to the endothelium and blockage of the vessels.

Indication: For the treatment of patients with predominantly classic subfoveal choroidal neovascularization due to age-related macular degeneration, pathologic myopia or presumed ocular histoplasmosis syndrome. Verteporfin can also be used to destroy tumors.

Associated Conditions: Subfoveal Choroidal Neovascularization (CNV)

Associated Therapies: -

Clinical Trials

Photo-induction as a Means to Improve Cisplatin Delivery to Pleural Malignancies

Phase 1

Terminated

Conditions: Pleural Effusion, Malignant

Interventions: Drug: Cisplatin, liposomal
Drug: Verteporfin
Device: Device for Intrapleural Visudyne-mediated Low-Dose Photodynamic Therapy with integrated in situ light dosimetry

First Posted Date: 2016-03-09

Last Posted Date: 2019-03-20

Lead Sponsor: Centre Hospitalier Universitaire Vaudois

Target Recruit Count: 1

Registration Number: NCT02702700

Locations: 🇨🇭
Oncology Department, Centre Hospitalier Universitaire Vaudois (CHUV), Lausanne, Vaud (VD), Switzerland

Adjunctive Photodynamic Therapy + Aflibercept vs. Afilbercept Alone for PDA in NV AMD

Not Applicable

Withdrawn

Conditions: Neovascular Age-related Macular Degeneration

Interventions: Drug: Aflibercept
Drug: Triamcinolone Acetonide
Drug: Verteporfin

First Posted Date: 2015-05-29

Last Posted Date: 2017-07-26

Lead Sponsor: Duke University

Registration Number: NCT02457026

Locations: 🇺🇸
Duke Eye Center, Durham, North Carolina, United States

A Study Testing if Medicine Can Make Pigment Epithelium Detachments Regress and Stabilize the Vision in Eyes

Not Applicable

Terminated

Conditions: Macular Degeneration
Retinal Detachment

Interventions: Drug: Aflibercept
Drug: Verteporfin

First Posted Date: 2012-12-11

Last Posted Date: 2015-09-15

Lead Sponsor: Norwegian University of Science and Technology

Target Recruit Count: 9

Registration Number: NCT01746875

Locations: 🇳🇴
Department of Neuroscience, NTNU, Trondheim, Norway

Lucentis KAV Study

Phase 3

Completed

Conditions: Age Related Macular Degeneration

Interventions: Drug: Ranibizumab
Drug: Verteporfin

First Posted Date: 2012-04-04

Last Posted Date: 2012-04-04

Lead Sponsor: The Ludwig Boltzmann Institute of Retinology and Biomicroscopic Laser Surgery

Target Recruit Count: 51

Registration Number: NCT01570608

Locations: 🇦🇹
Department of OPhthalmology Medical center east, Vienna, Austria
🇦🇹
Department of Ophthalmology Rudolf foundation Clinic, Vienna, Austria
🇦🇹
Department of Ophthalmology, Hospital Hietzing, Vienna, Austria

Ranibizumab Versus Low-fluence Photodynamic Therapy in the Treatment of Chronic Central Serous Chorioretinopathy

Phase 1

Completed

Conditions: Chronic Central Serous Chorioretinopathy

Interventions: Drug: Verteporfin
Drug: ranibizumab

First Posted Date: 2011-03-29

Last Posted Date: 2013-05-27

Lead Sponsor: Jang Won Heo

Target Recruit Count: 34

Registration Number: NCT01325181

Locations: 🇰🇷
• Department of Ophthalmology, Seoul National University College of Medicine, Seoul, Gyeonggi-do, Korea, Republic of

Ranibizumab Versus PDT for Presumed Ocular Histoplasmosis

Phase 2

Conditions: Presumed Ocular Histoplasmosis (POHS)

Interventions: Drug: ranibizumab
Drug: verteporfin

First Posted Date: 2007-10-19

Last Posted Date: 2009-04-16

Lead Sponsor: Barnes Retina Institute

Target Recruit Count: 30

Registration Number: NCT00546936

Locations: 🇺🇸
Barnes Retina Institute, St. Louis, Missouri, United States
🇺🇸
Macula-Retina-Vitreous Service, Midwest Eye Institute, Indianapolis, Indiana, United States

Ranibizumab and Reduced Fluence PDT for AMD

Phase 2

Completed

Conditions: Macular Degeneration

Interventions: Drug: ranibizumab
Drug: verteporfin

First Posted Date: 2007-09-11

Last Posted Date: 2013-06-07

Lead Sponsor: Texas Retina Associates

Target Recruit Count: 60

Registration Number: NCT00527475

Locations: 🇺🇸
California Retina Consultants & Research Foundation, Santa Barbara, California, United States
🇺🇸
Associated Retinal Consultants, Ann Arbor, Michigan, United States
🇺🇸
Texas Retina Associates, Arlington, Texas, United States